Groningen, the Netherlands, Oct 8, 2012 / B3C newswire / – Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it has signed a Research and License Option Agreement with Crucell Holland B.V. (“Crucell”), the Dutch developer of vaccines and antibodies. Crucell is one of the Pharmaceutical Companies of Johnson… Continue reading Mucosis Signs Research and License Option Agreement with Crucell
Category: news
ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant
Hørsholm and Copenhagen, Denmark, and Groningen, the Netherlands, September 25, 2012 / B3C newswire / – Biotech companies ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen today announced that they have been awarded a Eurostars(TM) grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine.… Continue reading ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant
Prosensa Named a Fierce 15 Biotech Company ‘One of the most promising private biotechnology companies in the industry’
Leiden, The Netherlands – 19 September 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has been named by FierceBiotech as one of 2012’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
Mucosis Appoints Thomas Johnston to CEO
Groningen, the Netherlands, Sept 17, 2012 / B3C newswire / – Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving… Continue reading Mucosis Appoints Thomas Johnston to CEO
Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study
Ghent, Belgium, July 9, 2012. Pronota NV, a company dedicated to the development of best-in-class diagnostics for early detection of life-threatening conditions, announced today that it has successfully validated its mid-gestation pre-eclampsia screening test. This test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration… Continue reading Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study
